secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001193125-25-148922
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma stockholders elect four Class II directors, ratify Ernst & Young as auditor
--------------------------------------------------------------------------------

- Elect directors Richard Lowenthal, Peter Kolchinsky, Brenton Saunders, Peter Thompson to 2028 term.
- Lowenthal receives 64.9M votes for, 3.0M withheld; Kolchinsky 55.8M for, 12.1M withheld.
- Saunders gets 56.2M for, 11.8M withheld; Thompson gets 61.8M for, 6.1M withheld.
- Broker non-votes on director election: 9.6M shares for each nominee.
- Auditor ratification passes with 77.3M for, 0.2M against; no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525148922/0001193125-25-148922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525148922/d15622d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-148922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer